Cargando…

Determining the genetic basis of anthracycline-cardiotoxicity by molecular response QTL mapping in induced cardiomyocytes

Anthracycline-induced cardiotoxicity (ACT) is a key limiting factor in setting optimal chemotherapy regimes, with almost half of patients expected to develop congestive heart failure given high doses. However, the genetic basis of sensitivity to anthracyclines remains unclear. We created a panel of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knowles, David A, Burrows, Courtney K, Blischak, John D, Patterson, Kristen M, Serie, Daniel J, Norton, Nadine, Ober, Carole, Pritchard, Jonathan K, Gilad, Yoav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	eLife Sciences Publications, Ltd 2018
Materias:	Genetics and Genomics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6010343/ https://www.ncbi.nlm.nih.gov/pubmed/29737278 http://dx.doi.org/10.7554/eLife.33480

Ejemplares similares

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Anthracycline-induced cardiotoxicity and senescence
por: Booth, Laura K., et al.
Publicado: (2022)

The Effect of Freeze-Thaw Cycles on Gene Expression Levels in Lymphoblastoid Cell Lines
por: Çalışkan, Minal, et al.
Publicado: (2014)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
por: Vuong, Jacqueline T., et al.
Publicado: (2022)

The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014)

Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018)

Metabolic Aspects of Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021)

Genetics of Anthracycline-Associated Cardiotoxicity
por: Al-Otaibi, Talal Khalid, et al.
Publicado: (2022)

Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
por: Volkova, Maria, et al.
Publicado: (2011)

Cardiotoxicity of anthracycline therapy: current perspectives
por: Valcovici, Mihaela, et al.
Publicado: (2016)

Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021)

Coronary microcirculation damage in anthracycline cardiotoxicity
por: Galán-Arriola, Carlos, et al.
Publicado: (2021)

Genetic Variation, Not Cell Type of Origin, Underlies the Majority of Identifiable Regulatory Differences in iPSCs
por: Burrows, Courtney K., et al.
Publicado: (2016)

Selective protection of human cardiomyocytes from anthracycline cardiotoxicity by small molecule inhibitors of MAP4K4
por: Golforoush, Pelin A., et al.
Publicado: (2020)

Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy
por: Broeyer, F. J. F., et al.
Publicado: (2008)

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
por: Chung, Woo-Baek, et al.
Publicado: (2016)

What is considered cardiotoxicity of anthracyclines in animal studies
por: Georgiadis, Nikolaos, et al.
Publicado: (2020)

What is considered cardiotoxicity of anthracyclines in animal studies
por: Georgiadis, Nikolaos, et al.
Publicado: (2020)

Anthracycline-Induced Cardiotoxicity: Remembering the Forgotten Ventricle
por: Liu, Jennifer E.
Publicado: (2020)

The Interplay Between Autophagy and Senescence in Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021)

Understanding Anthracycline Cardiotoxicity From Mitochondrial Aspect
por: Huang, Junqi, et al.
Publicado: (2022)

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
por: Ibanez, Borja, et al.
Publicado: (2022)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
por: Tantawy, Marwa, et al.
Publicado: (2020)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
por: Sobiborowicz-Sadowska, Aleksandra M., et al.
Publicado: (2023)

Metformin to Prevent Anthracycline Cardiotoxicity?: That Would Be Sweet!
por: El-Rayes, Malak, et al.
Publicado: (2023)

Batch effects and the effective design of single-cell gene expression studies
por: Tung, Po-Yuan, et al.
Publicado: (2017)

The Genetic and Mechanistic Basis for Variation in Gene Regulation
por: Pai, Athma A., et al.
Publicado: (2015)

Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity
por: Ma, Xiao, et al.
Publicado: (2020)

Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death
por: Popelová, O, et al.
Publicado: (2009)

Sodium nitroprusside induces cell death and cytoskeleton degradation in adult rat cardiomyocytes in vitro: implications for anthracycline-induced cardiotoxicity
por: Chiusa, M., et al.
Publicado: (2012)

A non-coding GWAS variant impacts anthracycline-induced cardiotoxic phenotypes in human iPSC-derived cardiomyocytes
por: Wu, Xi, et al.
Publicado: (2022)

Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
por: Balaji, Swetha, et al.
Publicado: (2023)

Intracellular magnesium concentrations and acute anthracycline-induced cardiotoxicity.
por: Sartori, S., et al.
Publicado: (1991)

Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
por: Choi, Hyoung Soo, et al.
Publicado: (2010)

Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors
por: Sadurska, Elżbieta
Publicado: (2015)

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
por: Hu, Hui-Min, et al.
Publicado: (2018)

Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
por: Henninger, Christian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vrciav226es9e82b2s10r97m8p